A 1904 revolt against mandatory smallpox inoculation taught Brazilian health officials a deadly lesson on how to vaccinate a skeptical public. Today President Bolsonaro seems to ignore that history.
The vaccines that will first be used to prevent the spread of COVID-19 will have gone through a special approval process with the FDA. but just what is this expedited process?
Australia is still aiming to start vaccinating high-risk groups from March. Why the delay?
With COVID-19 vaccine announcements making headlines, non-scientists need to know what clinical trial results mean. Here are some key points to look for in vaccine trial reports.
Unprecedented efforts are driving the global push for a safe and effective vaccine. If and when we have one (or more), here's how it's likely to be rolled out in Australia.
It's hoped the NHS's use of celebrity endorsement will influence the uptake of the COVID-19 vaccine – and research backs that up.
There are three promising COVID-19 trials.
We're on the road again. Getting enough COVID-19 vaccine to where it's needed in a given time frame is the next logistical hurdle.
Governments can do much to ensure mass vaccination of their citizens, particularly in the name of public health. But there needs to be careful examination of where that might breach human rights.
Vaccines are being touted as taking seven to ten years to develop. But you shouldn't be worried that COVID vaccines only took less than a year.
There is now a third vaccine that prevents COVID-19 infections. It isn't quite as effective as the other two vaccines but it has advantages that may make it the frontrunner.
Amid good news on the vaccine trial-front, Australia must think more carefully about how a national roll-out would work.
Join The Conversation for a virtual discussion with leading scientists about what life will be like with the COVID-19 vaccine.
The United Nations recently asked a group of experts across the world to recommend ways to persuade people to take a COVID-19 vaccine. Here is a summary of their suggestions.
Data coming through from phase 3 trials are encouraging. But participants don't represent the whole community — so we can't be sure these vaccines will work as well in everyone.
COVID-19 vaccines are at risk of being undermined by vaccine hesitancy. Pharma must take steps to ensure transparency in data monitoring committees and trial data to build public trust in vaccines.
Governments can't force people to be vaccinated, but they can penalise those who don't.
In the disturbing scenario of human-to-mink-to-human COVID-19 transmission, the virus may mutate in mink prior to re-infecting people. That possibility makes vaccine design even more crucial.
Inaction over the next few months could cost tens of thousands of lives. Here are things you should do now to stay safe and to stop the spread of the coronavirus.
Early data shows that vaccines work for older people who are more at risk of severe COVID-19.